Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
PAI-1 antagonists: the promise and the peril.
Douglas E. Vaughan
*
*
Corresponding author for this work
Medicine, Cardiology Division
Research output
:
Contribution to journal
›
Article
›
peer-review
25
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'PAI-1 antagonists: the promise and the peril.'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Plasminogen Activator inhibitor-1 (PAI-1)
100%
Fibrinolytic System
100%
Fibrinolytic Activity
66%
Human Disease
33%
Therapeutic Potential
33%
Tissue Plasminogen Activator (t-PA)
33%
Acute Myocardial Infarction
33%
Defense Mechanisms
33%
Plasminogen Activator
33%
Fast-acting
33%
Acute Setting
33%
Thrombolytic Agents
33%
Direct Way
33%
Intravascular Thrombosis
33%
Endogenous Defense
33%
Medicine and Dentistry
Fibrinolysis
100%
Plasminogen Activator Inhibitor-1
100%
Diseases
20%
Tissue Plasminogen Activator
20%
Plasminogen Activator
20%
Thrombosis
20%
Acute Heart Infarction
20%
Apoplexy
20%
Thrombolytic Drug
20%
Pharmacology, Toxicology and Pharmaceutical Science
Plasminogen Activator Inhibitor 1
100%
Fibrinolytic Agent
100%
Cerebrovascular Accident
16%
Acute Heart Infarction
16%
Disease
16%
Thrombosis
16%
Tissue Plasminogen Activator
16%
Plasminogen Activator
16%